We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Assura Plc | LSE:AGR | London | Ordinary Share | GB00BVGBWW93 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.46 | 1.17% | 39.64 | 39.46 | 39.54 | 39.56 | 38.50 | 38.50 | 5,958,462 | 16:35:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Real Estate Agents & Mgrs | 157.8M | -28.8M | -0.0089 | -44.40 | 1.27B |
14 November 2024
Assura plc
Confirmation of secondary listing on the Johannesburg Stock Exchange
Assura plc ("Assura" or the "Company"), the UK's leading diversified healthcare REIT, is pleased to confirm that the Johannesburg Stock Exchange ("JSE") has granted approval to Assura for a secondary listing on the Main Board of the JSE. The commencement of trading is expected to take effect on Thursday, 21 November 2024.
The Company has released a pre-listing announcement ("PLA") in relation to a secondary inward listing on the Main Board of the JSE by way of an introduction.
Assura continues to see opportunities in providing critical healthcare infrastructure and believes that this secondary listing will provide a new potential pool of capital to fund the Company's continued growth.
In particular, the listing will enable Assura to:
· give South African investors a local platform to more easily invest in and trade Assura shares;
· broaden the Company's shareholder base with new South African investors;
· increase liquidity for shareholders; and
· diversify the Company's shareholder base and position it for future growth.
The Company will not place or issue any new Assura shares in connection with its application for a secondary listing on the JSE and will remain listed on the Equity Shares (Commercial Companies) category (ESCC) of the Official List in London.
HSBC is acting as Listing Co-ordinator and Corporate Broker and Nedbank Corporate and Investment Banking, a division of Nedbank Limited, as Corporate Advisor and JSE Sponsor.
Jonathan Murphy, CEO, said:
"We are delighted that our secondary listing on the Johannesburg Stock Exchange, which we believe will contribute to liquidity in our shares, has been approved.
As the UK's leading diversified healthcare REIT, Assura offers an attractive proposition to South African investors. We look forward to welcoming them onto our share register. Our high quality assets offer long-term secured and growing income, underpinned by the long-term structural demand for healthcare services."
- Ends -
For more information, please contact:
Assura plc |
Tel: 0161 515 2043 |
David Purcell, Investor Relations Director |
Email: Investor@assura.co.uk |
FGS Global Gordon Simpson Grace Whelan
|
Email: Assura@fgsglobal.com |
HSBC Bank Plc Chloe Ponsonby Jonathan Surr Louis Davies |
Tel: 020 7991 8888 |
Notes to Editors
Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.
A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 30 September 2024, Assura's portfolio was valued at £3.2 billion and has a strong track record of growing financial returns and dividends for shareholders.
At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).
Further information is available at www.assuraplc.com
*EPRA is a registered trademark of the European Public Real Estate Association
1 Year Assura Chart |
1 Month Assura Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions